Overview

N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Critically ill patients frequently undergo contrast enhanced computed tomography (CT) to establish diagnoses and direct management. Contrast agents can disturb kidney function and result in kidney dysfunction. The investigators investigated the effects of high dose N-acetylcysteine (NAC) or placebo, in addition to hydration, in preventing kidney dysfunction following contrast enhanced CT) in critically ill adults in the intensive care units of two teaching hospitals.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
St. Michael's Hospital, Toronto
Unity Health Toronto
Collaborators:
Fran Priestap
Martin, Claudio M., M.D.
Treatments:
Acetylcysteine
N-monoacetylcystine